Scientific Industries Announces Third Quarter 2025 Results And Launch of VIVID’s New AI-Powered Feature

Rhea-AI Summary

Scientific Industries (OTCQB: SCND) reported third-quarter 2025 results and launched an AI feature for its VIVID WORKSTATION on November 20, 2025.

Key Q3 figures: revenues $1.404M, gross margin 45.5%, net income $3.994M and EPS $0.34. The company reported $8.3M in cash, cash equivalents and investments as of September 30, 2025. Management completed the Genie division sale on August 7, 2025, producing a reported gain that materially affected results. Product highlights include a 27% YoY VIVID sales increase, Torbal division sales up 15% YTD, and DOTS platform enhancements.

Positive

• VIVID sales +27% YoY
• Torbal division sales +15% YTD
• Q3 net income $3.994M
• Q3 EPS $0.34
• Cash and investments $8.3M as of Sep 30, 2025
• Gain on Genie sale $5,263,400

Negative

• Gross margin declined to 45.5% in Q3 from 51.0% prior year
• Nine-month revenues decreased 2.5% to $3.427M
• Bioprocessing revenue down $141,700 for the quarter
• Loss from continuing operations $5.4347M for nine months
• Customer purchase delays due to tariffs and reduced government funding

TORBAL DIVISION SALES UP 15% YTD
LAUNCH OF VIVID’S FIRST AI-POWERED FEATURE
SECOND GENERATION VIVID-ONE LAUNCH SCHEDULED FOR Q1 CY26

Investor Call to be held Thursday, November 20^th at 11:00 a.m. Eastern Time

BOHEMIA, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Scientific Industries, Inc. (OTCQB: SCND), a leading developer of digitally simplified bioprocessing solutions and vision-based pill counters, today reported financial results for the three and nine months ended September 30, 2025, and announced the launch of a new AI-enabled feature for its VIVID WORKSTATION.

Business Highlights:

• Launched an innovative prescription label documentation and verification feature for the VIVID WORKSTATION, harnessing AI technology
• Achieved a 27% year-over-year sales increase for VIVID products
• Torbal Division sales up 15% year-over-year
• DOTS MPS Platform augmented with single use nanoparticles for baffled flasks.
  
  

2025 Third Quarter Financial Overview:

• Net revenues totaled $1.4 million versus $1.3 million in the prior year period
  • Genie Division sold on August 7, 2025
• Gross profit was $0.6 million, compared to $0.7 million in the prior year period
• Gross margin was 45.5%, compared to 51.0% in the prior year period
• Cash, cash equivalents and investments were $8.3 million as of September 30, 2025
  
  

Management Discussion

Helena Santos, Chief Executive Officer of Scientific Industries, stated: “The divestiture of our Genie brand portfolio has sharpened our focus on our high-growth segments, including our pill counting business. With the introduction of AI-driven capabilities in the VIVID WORKSTATION, we are redefining innovation in pharmacy automation. This upgrade not only strengthens compliance and accountability but also delivers significant cost efficiencies for our customers. Our unwavering commitment to continuous improvement—across hardware, firmware, and software—ensures that VIVID pill counters remain at the forefront of automated pill counting solutions.”

“Our relentless focus on innovation – spanning hardware, firmware, and software—keeps VIVID pill counters at the forefront of automated pill counting solutions. This commitment not only drives future revenues, but also builds a powerful and enduring platform of value for our customers,” concluded Ms. Santos.

John Moore, Chairman said, “Scientific Bioprocessing continues to innovate with the introduction of the world’s first dissolved oxygen sensor designed for baffled flasks. Nine out of ten pilot testers were surprised to discover that their cultures were severely oxygen-limited, meaning they were not producing their Gene of Interest (GOI) as expected. These insights have led to major new customer wins, seamless workflow integrations, and repeat orders. Breakthrough findings like these—helping scientists improve the reproducibility of their experiments—are emerging with each new component added to the DOTS platform. Customers are already looking forward to the pilot results of our new pH sensor, expected in the first quarter of 2026. In the meantime, customer budgets have been affected by tariffs and reduced government funding for scientific research. We have subsequently experienced delays in customer purchases. Despite these challenges, we remain optimistic about the fourth quarter and 2026 and are excited about the future.” 

2025 Third Quarter and Nine-Month Financial Review

Net revenues for the three months ended September 30, 2025, increased $69,600, or 52.2% to $1,404,000 from $1,334,400 for the three months ended September 30, 2024, primarily due to an increase in revenues from the Torbal Division of the Benchtop Laboratory Equipment Operations. Driven by growing demand for VIVID products. Bioprocessing Systems Operations revenues reflected a $141,700 decrease for the quarter due to overall softness in the market and requirements for products not yet available by the Company.

Net revenues for the nine months ended September 30, 2025, decreased $87,500, or (2.5%) to $3,427,100 from $3,514,600 for the nine months ended September 30, 2024, primarily due to decreased Bioprocessing Systems Operations revenues, reflecting an overall softness in the market. The decrease was partially offset by increased revenues from the Torbal Division, with total revenues increased $356,700, or 15% to $2,737,300 for the nine months ended September 30, 2025 compared to $2,380,600 in the prior year period.

The gross profit margin for the three and nine months ended September 30, 2025 was 45.5% and 39.8%, compared to 51.0% and 44.1%, respectively, for the prior year periods, primarily due to the sale of the Genie Division on August 7, 2025. Additionally, increases in material costs due to tariffs for Torbal OEM products, and lower gross margins for Bioprocessing products due to fixed costs on lower sales.

Operating expenses decreased $84,800 and $439,600, to $2,160,900 and $6,797,700, respectively in the three-month and nine-month periods ended September 30, 2025, compared to $2,245,700 and $7,237,300, respectively in the same period in 2024, primarily as a result of decreased expenses resulting from reduced costs by the Bioprocessing Systems Operations.

The Company reflected Total Other Income, Net of $5,526,900 and $5,582,300 for the three and nine months ended September 30, 2025, respectively compared to $78,500 and $169,000, respectively, due to a gain on sale of $5,263,400 from the Genie Division sale on August 7, 2025 to Ohaus Corporation’s affiliate, Troemner, LLC.

As a result, the Company posted net income of $3,994,400, and $692,200 or $0.34 and $0.06 earnings per share for the three and nine month periods ended September 30, 2025, respectively, compared to net losses of $1,180,100 and $4,515,400 or $(0.11) and $(0.43) loss per share for the three and nine month periods ended September 30, 2024, respectively.

Conference Call Details

Scientific Industries will conduct a conference call to discuss financial results for the third quarter of 2025 on Thursday, November 20, 2025, at 11:00 A.M. ET. Interested parties can access the conference call by dialing (844) 481-2706 or (412) 317-0662 (international). A webcast of the call will be available on the Company’s Investor Relations page at https://www.scientificindustries.com/investor-relations/ or at https://app.webinar.net/85AGrAdVN1d.

A replay of the call will be available through November 27, 2025, at (855) 669-9658 or (412) 317-0088 (international), replay access code: 4098504, or for 30 days at https://www.scientificindustries.com/investor-relations/.

About Scientific Industries, Inc.

Scientific Industries (OTCQB: SCND) designs, manufactures, and markets bioprocessing systems under the product name DOTS, and vision-based pill counters under the VIVID brand in addition to weighing instruments. Scientific Industries’ products are generally used in laboratories of universities, hospitals, pharmaceutical companies, and pharmacies. To learn more visit www.scientificbio.com, www.torbalscales.com, and www.pillcounters.com.

Safe Harbor Statement

Statements made in this press release that relate to future events, performance or financial results of the Company are forward-looking statements which involve uncertainties that could cause actual events, performance or results to materially differ. The Company undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statement should be read in conjunction with the additional information about risks and uncertainties set forth in the Company's Securities and Exchange Commission reports, including our annual report on Form 10-K.

Company Contact:
Helena R. Santos	or:
CEO and President	Joe Dorame
Phone: 631-567-4700	Lytham Partners, LLC
hsantos@scientificindustries.com	Phone: (602)889-9700
info@scientificindustries.com	SCND@lythampartners.com

---FINANCIAL TABLES FOLLOW—

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
			30-Sep-25				31-Dec-24
ASSETS			(Unaudited	)
Cash and Cash Equivalents		$	1,162,600			$	587,900
Investment Securities			7,131,100				1,985,000
Other Current Assets			3,595,000				5,714,800
Intangibles Assets and Goodwill			564,600				861,300
Other Long Term Assets			2,104,100				2,411,800
Total Assets		$	14,557,400			$	11,560,800
LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities		$	1,553,500			$	1,747,000
Long-Term Liabilities			542,200				694,400
Shareholders' Equity			12,461,700				9,119,400
Total Shareholders' Equity & Liabilities		$	14,557,400			$	11,560,800

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
		For the Three Months Ended				For the Three Months Ended				For the Nine Months Ended				For the Nine Months Ended
		30-Sep-25				30-Sep-24				30-Sep-25				30-Sep-24
Revenues		$	1,404,000			$	1,334,400			$	3,427,100			$	3,514,600
Gross Profit			638,600				679,900				1,363,000				1,551,500
Operating Expenses			2,160,900				2,245,700				6,797,700				7,237,300
Loss From Continuing Operations			(1,522,300	)			(1,565,800	)			(5,434,700	)			(5,685,800	)
Total Other Income, Net			5,526,900				78,500				5,582,300				169,000
Loss From Continuing Operations Before Income Tax Expense			4,004,600				(1,487,300	)			147,600				(5,516,800	)
Income Tax Expense			15,300				–				15,300				–
Loss From Continuing Operations			3,989,300				(1,487,300	)			132,300				(5,516,800	)
Gain From Discontinued Operations, Net of Tax			5,100				307,200				559,900				1,001,400
Net Income (Loss)			3,994,400				(1,180,100	)			692,200				(4,515,400	)
Comprehensive Gain (Loss)			(29,800	)			113,600				249,800				69,100
Total Comprehensive Loss		$	3,964,600			$	(1,066,500	)		$	942,000			$	(4,446,300	)
Basic and Diluted income (loss) per common share		$	0.34			$	(0.11	)		$	0.06			$	(0.43	)
Weighted average number of outstanding shares (basic):			11,712,567				10,503,599				11,150,939				10,443,029

FAQ

What did Scientific Industries (SCND) report for Q3 2025 revenue and EPS?

SCND reported Q3 2025 revenue $1.404M and EPS $0.34.

How did the Genie division sale affect Scientific Industries' Q3 2025 results?

The Genie sale closed on August 7, 2025 and produced a reported gain of $5,263,400, materially improving net income.

What is the new AI feature for VIVID WORKSTATION announced on November 20, 2025?

The company launched an AI-powered prescription label documentation and verification feature for the VIVID WORKSTATION.

What is Scientific Industries' cash and investment position as of September 30, 2025?

Cash, cash equivalents and investments totaled $8.3M as of September 30, 2025.

How did Torbal division sales perform in 2025 and what does it mean for SCND?

Torbal division sales were up 15% year-over-year, supporting overall revenue growth for VIVID-related demand.

Why did gross margins decline in Q3 2025 for SCND?

Margins fell to 45.5% due to the Genie sale, higher Torbal material costs from tariffs, and lower Bioprocessing margins on reduced volumes.